Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CFSAN carb survey

This article was originally published in The Tan Sheet

Executive Summary

An FDA study reveals that 61% of consumers "have heard of" omega-3 fatty acids, compared to 95% who have heard of saturated fat and 67% who have heard of trans fat, the Center for Food Safety & Applied Nutrition announces Nov. 22. "Fats and Carbs: A Snapshot of Consumer Knowledge from a Recent FDA survey" is the center's ninth Health and Diet Survey, conducted "to measure public awareness, knowledge, attitudes and reported behavior" related to nutrition. The random-digit-dialing telephone survey questioned a "nationally representative" sample of 1,798 consumers from October 2004 to January 2005. Data show 53% of consumers tried low carb products, while 30% are unlikely to try such products despite having heard of them. Among those limiting carbs in their diet, 54% do so to lose weight while 37% do so "for other purposes." CFSAN also finds that "calories and fat are considered more important than carb in losing weight" by consumers, with 61% trying to limit fat intake, 48% trying to limit calories and 41% trying to limit carbs...

You may also be interested in...

RB Doubles R&D Spend In Search Of 'Game Changing’ OTC Innovation

With Reckitt's OTC sales falling 3% in 2020, the firm has committed to doubling its R&D spend in search of breakthrough product innovations.

JHL Becomes Eden And Announces Denosumab Progress

Taiwan’s JHL Biotech has rebranded itself as Eden Biologics at the same time as it has announced progress on clinical trials for its denosumab biosimilar candidate.

Australia’s Starpharma Plans To Launch COVID-Killing Nasal Spray In Europe

Starpharma's COVID-busting Viraleze antiviral nasal spray will soon be available across Europe, included the UK. But will it fall foul of local evidence requirements, for example in France, where the country's medicines agency has halted the sale of Pharma & Beauty (P&B) Group's COV-Defense spray until its efficacy against COVID has been confirmed by human-based studies?





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts